Back to search

Peptide record

TPDB42784

R-lycosin-I Anticancer Cell-penetrating Peptides standard
23 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB42784
R-lycosin-I
Anticancer Cell-penetrating Peptides
Cancer-related peptides Delivery and barrier-penetrating peptides
CancerPPD 2.0 CPPsite3.0
standard
No
A 23-aa standard natural multi-activity (Anticancer and Cell-penetrating Peptides) peptide sequence curated from CancerPPD 2.0 and CPPsite3.0, with an available 3D structural model.
C-terminal: Amidation N-terminal: Acetylation
Sequence
Ac-RGWFRAMRSIARFIARERLREHL-NH2
Physicochemical Analysis
C130H211N47O29S1
NDCQKPTYV
R
2928.46
12.53
8
2
11
+5
4.22
-0.622
80.87
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
5500
187.81
1
Residue Composition
number
3
A
7
R
0
N
0
D
0
C
2
E
0
Q
1
G
1
H
2
I
2
L
0
K
1
M
2
F
0
P
1
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 3 R: 7 N: 0 D: 0 C: 0 E: 2 Q: 0 G: 1 H: 1 I: 2 L: 2 K: 0 M: 1 F: 2 P: 0 S: 1 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
23
C130H211N47O29S1
2928.46
12.53
+5
4.22
-0.622
Amidation
L
Amphipathic
Linear
Acetylation
N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O
Evidence Records 1 records
Evidence 1 Activity

Activity

Cell-penetrating Peptides

Target

A549, HeLa, MDA-MB-231,Pc-3 Cell

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L Amphipathic
Protein derived
FITC-labelled
Cytoplasm
The internalization is dose-and time-dependent , while at 15 μM, the amount of fluorescence-marked cells in the R-lycosin-I-treated group was approximately 9 times higher than that observed for lycosin-I at 0.5 h, approximately 16 times at 1 h and 20 times at 2 h.
Endocytosis
In vitro and ex vivo
CCGGGGGTTSCCCCSCCCCC
Additional Detail Fields 1 fields
CCGGGGGTTSCCCCSCCCCC